Health Catalyst Inc (HCAT) concluded trading on Thursday at a closing price of $3.84, with 0.47 million shares of worth about $1.79 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -54.93% during that period and on April 17, 2025 the price saw a gain of about 2.40%. Currently the company’s common shares owned by public are about 70.21M shares, out of which, 66.95M shares are available for trading.
Stock saw a price change of 0.26% in past 5 days and over the past one month there was a price change of -14.86%. Year-to-date (YTD), HCAT shares are showing a performance of -45.69% which decreased to -30.56% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.56 but also hit the highest price of $9.24 during that period. The average intraday trading volume for Health Catalyst Inc shares is 803.89K. The stock is currently trading -7.69% below its 20-day simple moving average (SMA20), while that difference is down -15.98% for SMA50 and it goes to -42.48% lower than SMA200.
Health Catalyst Inc (NASDAQ: HCAT) currently have 70.21M outstanding shares and institutions hold larger chunk of about 78.23% of that.
The stock has a current market capitalization of $269.61M and its 3Y-monthly beta is at 1.58. It has posted earnings per share of -$1.15 in the same period. It has Quick Ratio of 1.42 while making debt-to-equity ratio of 1.10. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for HCAT, volatility over the week remained 8.79% while standing at 7.82% over the month.
Stock’s fiscal year EPS is expected to rise by 4.93% while it is estimated to increase by 43.59% in next year. EPS is likely to shrink at an annualized rate of 36.28% for next 5-years, compared to annual growth of 38.24% made by the stock over the past 5-years.
Coverage by KeyBanc Capital Markets stated Health Catalyst Inc (HCAT) stock as an Overweight in their note to investors on January 08, 2025, suggesting a price target of $9 for the stock. On April 10, 2024, KeyBanc Capital Markets Downgrade their recommendations, while on January 03, 2024, Evercore ISI Upgrade their ratings for the stock with a price target of $11. Stock get an Overweight rating from Barclays on January 03, 2024.
